Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
Status:
Terminated
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This study is designed primarily to establish efficacy and estimate resource utilization. The
short-term hypothesis is that the dose of capecitabine (825 mg/m2 twice/day 5 days per week)
during the course of radiation therapy is efficacious in locally advanced, non-metastatic
rectosigmoid carcinoma and will improve resectability. The long-term working hypothesis is
that if 3-D CRT is combined with the potentiating and additive effect of capecitabine one
hopes to see improved and durable tumor response and survival with acceptable toxicity. In
addition, it is expected that the simplicity of using an oral agent (capecitabine) will be
associated with reduced cost and resource utilization.